Back to top

Analyst Blog

GlaxoSmithKline (GSK - Analyst Report) recently announced data from a phase III trial (n = 940) evaluating its oncology drug, Votrient (pazopanib). The randomized, double-blind, placebo-controlled phase III trial evaluated the use of Votrient as maintenance therapy in women suffering from epithelial ovarian, fallopian tube or primary peritoneal cancer, whose disease did not worsen after receiving standard debulking surgery  and first-line chemotherapy treatment.

The study met its primary endpoint of progression free survival (PFS/the time a patient lived without worsening of their disease). In the Votrient arm of the study, median PFS of 17.9 months was observed as compared to 12.3 months in the placebo arm, representing an improvement of 5.6 months. It was observed that treatment with Votrient reduced the risk of the disease worsening by 23%.

The company said that there were insufficient events to estimate median overall survival (OS) at the time of data cut off. However, no difference in survival was found between the two arms of the trial in the interim analysis.

Glaxo plans to submit the marketing applications for the approval of Votrient in the ovarian cancer indication during the course of the year. Votrient is already marketed for the treatment of patients with advanced renal cell carcinoma. Last year, the drug’s label was expanded to include advanced soft tissue sarcoma.

We note that Glaxo’s oncology portfolio received a boost recently when two melanoma drugs, Tafinlar (dabrafenib) and Mekinist (trametinib) gained approval from the US Food and Drug Administration. While Tafinlar was approved for use in BRAF V600E mutation-positive unresectable or metastatic melanoma patients, Mekinist received clearance for the treatment of patients suffering from unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

Glaxo carries a Zacks Rank #3 (Hold). We are pleased with Glaxo’s label expansion efforts. Moreover, Glaxo boasts of a robust pipeline. A number of pipeline-related news is expected in the coming quarters. Given the declining sales from generic competition, we believe Glaxo’s pipeline must deliver. Companies that currently look attractive include Santarus, Inc. , Jazz Pharmaceuticals (JAZZ - Analyst Report) and Salix Pharmaceuticals (SLXP - Analyst Report). All the three carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 26.98 +10.17%
CANADIAN SO… CSIQ 38.30 +8.07%
BANCO DO BR… BDORY 16.78 +8.05%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%